Stock 1795 LOTUS PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

Pharmaceuticals

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
286.5 TWD -1.72% Intraday chart for Lotus Pharmaceutical Co., Ltd. +2.69% +5.33%
May. 11 Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 26 Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director CI

Business Summary

Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Number of employees: 1,099

Sales per Business

TWD in Million2022Weight2023Weight Delta
Pharmaceuticals
99.4 %
14,503 99.1 % 16,864 99.4 % +16.28%
Other
0.6 %
130 0.9 % 94 0.6 % -27.72%

Sales per region

TWD in Million2022Weight2023Weight Delta
United States
40.2 %
5,916 40.4 % 6,815 40.2 % +15.18%
South Korea
32.9 %
5,277 36.1 % 5,587 32.9 % +5.86%
Taiwan
14.2 %
0 0.0 % 2,413 14.2 % -
Others
12.6 %
3,439 23.5 % 2,144 12.6 % -37.66%

Managers

Managers TitleAgeSince
Petar Antonov Vazharov CEO
 Chief Executive Officer - 14-09-28
I ling Tian DFI
 Director of Finance/CFO - 16-10-31
Ying Ming Yue COO
 Chief Operating Officer - 22-11-30
Gwen Hsieh CIO
 Chief Investment Officer - 21-08-01
Manisha Chawla CTO
 Chief Tech/Sci/R&D Officer - 19-07-07
Edin Buljubašic CMP
 Compliance Officer - 22-11-30
Erica Yen IRC
 Investor Relations Contact - -
Bjartur Shen IRO
 Public Communications Contact - 18-01-15
Ryan Koh AUD
 Comptroller/Controller/Auditor - 22-11-09
Prashant Godse PRN
 Corporate Officer/Principal - 22-02-28

Members of the board

Members of the board TitleAgeSince
Vilhelm Wessman CHM
 Chairman 54 15-04-22
Thor Kristjansson BRD
 Director/Board Member 60 14-08-10
Hjörleifur Pálsson BRD
 Director/Board Member 61 15-04-22
Árni Harðarson BRD
 Director/Board Member 57 14-08-10
Petar Antonov Vazharov CEO
 Chief Executive Officer - 14-09-28
Mu Yao Ku BRD
 Director/Board Member - 14-09-28
Pannalin Mahawongtikul BRD
 Director/Board Member 59 -
Yves Hermes BRD
 Director/Board Member - 22-06-29
Phannalin Mahawongtikul BRD
 Director/Board Member - 22-06-29
Krisana Winitthumkul BRD
 Director/Board Member - 22-11-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 264,958,300 128,414,312 ( 48.47 %) 490,000 ( 0.1849 %) 48.47 %

Shareholders

NameEquities%Valuation
Celtic Holdings SCA
41.13 %
108,968,519 41.13 % 1 081 M NT$
FUJI PHARMA CO., LTD.
1.854 %
4,913,220 1.854 % 49 M NT$
Uni-President Asset Management Corp.
1.589 %
4,210,994 1.589 % 42 M NT$
Capital Investment Trust Corp.
0.5654 %
1,497,995 0.5654 % 15 M NT$
Yuanta Securities Investment Trust Co., Ltd.
0.4265 %
1,129,995 0.4265 % 11 M NT$
Fuh Hwa Securities Investment Trust Co., Ltd.
0.2914 %
771,996 0.2914 % 8 M NT$
SinoPac Securities Investment Trust Co., Ltd.
0.1223 %
323,996 0.1223 % 3 M NT$
Union Securities Investment Trust Co., Ltd.
0.0906 %
239,998 0.0906 % 2 M NT$
Mega International Investment Trust Co., Ltd.
0.0746 %
197,752 0.0746 % 2 M NT$
Taishin Securities Investment Trust Co., Ltd.
0.0521 %
137,998 0.0521 % 1 M NT$

Holdings

NameEquities%Valuation
FUJI PHARMA CO., LTD.
4.92%
 1,219,000 4.92% 12,316,654 $

Company contact information

Lotus Pharmaceutical Co., Ltd.

No. 277, Song Ren Road 17/F, Xin Yi District

110 58, Taipei

+

http://www.lotuspharm.com
address Lotus Pharmaceutical Co., Ltd.(1795)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Lotus Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
286.5 TWD
Average target price
393.2 TWD
Spread / Average Target
+37.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LOTUS PHARMACEUTICAL CO., LTD. Stock Lotus Pharmaceutical Co., Ltd.
+5.33% 2.39B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 332B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 210B
NOVARTIS AG Stock Novartis AG
+10.63% 209B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1795 Stock
  4. Company Lotus Pharmaceutical Co., Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW